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Mycolic acids are major and specific lipids of Myco-
bacterium tuberculosis cell envelope. Their synthesis
requires the condensation by Pks13 of a C22-C26 fatty
acid with the C50-C60 meromycolic acid activated by
FadD32, a fatty acyl-AMP ligase essential for myco-
bacterial growth. A combination of biochemical and
enzymatic approaches demonstrated that FadD32
exhibits substrate specificity for relatively long-chain
fatty acids. More importantly, FadD32 catalyzes
the transfer of the synthesized acyl-adenylate onto
specific thioesteracceptors, thus revealing the protein
acyl-ACP ligase function. Therefore, FadD32 might be
the prototype of a group ofM. tuberculosispolyketide-
synthase-associated adenylation enzymes possess-
ing such activity. A substrate analog of FadD32
inhibited not only the enzyme activity but also mycolic
acid synthesis and mycobacterial growth, opening
an avenue for the development of novel antimycobac-
terial agents.
INTRODUCTION
One decade after the publication of theMycobacterium tubercu-
losis genome sequence, impressive progress has been achieved
toward the discovery and the understanding of specific and
essential mycobacterial metabolic pathways. Among these is
the lipid metabolism of the tubercle bacillus to which a high
number of genes are dedicated. These lipids include mycolic
acids, very long-chain (up to C90) fatty acids (a-branched,
b-hydroxylated), which are major and very specific components
of the cell envelope of M. tuberculosis and play a crucial role in
its remarkable architecture and impermeability (Daffe´ and
Draper, 1998). Their biosynthesis is the target of the front-line
and highly efficient antituberculous drug isoniazid (Takayama
et al., 1972) and this pathway still represents an important reser-
voir of targets for the development of new antimycobacterial
drugs. Many enzymes of the pathway have been discovered,510 Chemistry & Biology 16, 510–519, May 29, 2009 ª2009 Elsevieramong which are the enzymes of the fatty acid synthase II
(FAS-II) system involved in the formation of the very long mero-
mycolic chain (C50–C60), and the transferases that introduce
methyl groups on this chain (for review, see Marrakchi et al.,
2008). The ultimate step in the pathway, the ‘‘mycolic condensa-
tion’’ of two long-chain fatty acids, has been shown to require at
least three enzymes encoded by the putative accD4-pks13-
fadD32 operon (Portevin et al., 2004, 2005). This gene cluster
is restricted to mycolic-acid-producing bacterial species, the
so-called Corynebacterineae suborder (Gande et al., 2004; Por-
tevin et al., 2004, 2005). AccD4 and FadD32 play a role in the acti-
vation of the substrates of the condensing enzyme, Pks13, and
all three proteins are essential for the viability of mycobacteria
(Portevin et al., 2004, 2005). AccD4 is a subunit of the acyl-CoA
carboxylase (ACC) complex that activates the a-branch ofmyco-
lates through a carboxylation step (Gande et al., 2007), whereas
FadD32, a fatty acyl-AMP ligase (FAAL), catalyzes the formation
of acyl-adenylates, proposed to be the ‘‘activated’’ form of the
very long meromycolic acid substrate in the mycolic condensa-
tion reaction (Portevin et al., 2005; Trivedi et al., 2004). Finally,
the reduction of the b-ketoacyl product formed after condensa-
tion by Pks13 is catalyzed by CmrA to yield the mature mycolic
acids (Lea-Smith et al., 2007).
FadD32, one of the 34 FadD proteins ofM. tuberculosis anno-
tated as putative fatty acyl-CoA synthetases (FACS), is amember
of theadenylate-formingenzymesuperfamilyPF00501 (Finnet al.,
2008) that includes the acyl- and aryl-CoA synthetases or ligases,
theadenylationdomainsof thenonribosomalpeptidesynthetases
(NRPS), and firefly luciferases. In the two-step reaction catalyzed
by enzymes of this superfamily, a carboxylated substrate is first
activatedwithATP, to formanacyl-adenylate (acyl-AMP) interme-
diate (Figure 1). In the second half-reaction, these enzymes cata-
lyze the formation of thioester of either CoA or acyl-carrier protein
(ACP) (Bar-Tana et al., 1972; Bar-Tana andRose, 1973; Hisanaga
et al., 2004). Based on their primary sequence similarity, which
was found to correlate with their functions, the M. tuberculosis
FadD proteins have been subdivided in two classes, namely,
(i) a large group of FadD proteins displaying the expected FACS
activity, and (ii) a small subset of FadD proteins, which includes
FadD32, displaying solely the FAAL activity (i.e., catalyzing only
the first half-reaction) (Figure 1) (Trivedi et al., 2004).Ltd All rights reserved
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FadD32 Acyl-AMP Ligase/ACP SynthetaseIn the present study, we report the biochemical and kinetic
characterization of the FAAL activity of FadD32.We also demon-
strate the ability of the protein to further transfer the synthesized
acyl-adenylate onto a thioester acceptor, an unrevealed acyl-
ACP ligase function that shed light on the cross talk between
some polyketide synthases and their associated adenylation
enzymes. In addition, as a first step in the design of mecha-
nism-based novel antimycobacterial agents, we synthesized
a substrate analog and showed that it inhibits both FadD32
activity and mycolic acid synthesis, and affects mycobacterial
survival.
Figure 1. Two-Step Chemical Reaction Catalyzed by Acyl-CoA/ACP
Synthetases
Fatty acyl-AMP ligases (FAAL) and fatty acyl-CoA or -ACP synthetases (FACS/
FAAS) catalyze the formation of the acyl-adenylate intermediate; only FACS/
FAAS are able to catalyze the second half reaction to yield fatty acyl CoA/ACP.
R corresponds to alkyl chain (CH3-(CH2)n-).Chemistry & Biology 16RESULTS
Characteristic Features of FadD32
The analysis of the Corynebacterineae genomes sequenced so
far revealed the strict conservation of the fadD32 gene within
the accD4-pks13-fadD32 cluster, with the encoded proteins
exhibiting high levels of sequence similarity (Portevin et al.,
2005). It also underlined the requirement of the fadD32-encoded
protein for mycolic acid biosynthesis, in agreement with the
essentiality of the gene in mycobacteria (Portevin et al., 2005).
The fadD32 open reading frame specifies a protein from the
ATP-dependent AMP-binding protein superfamily whose various
members catalyze mechanistically similar two-step reactions
(Figure 1). Alignment of the primary sequences of FadD32 with
a set of proteins catalyzing the acylation reaction using diverse
substrates revealed a few regions of high similarity and
conserved signature motifs, A3 to A10 (according to the nomen-
clature adopted for the NRPS adenylation domains [Marahiel
et al., 1997]), characteristic of these adenylate-forming proteins
(Ingram-Smith et al., 2006; Morsczeck et al., 2001) (Figure 2).
The crystal structures of the adenylate-forming enzymes (AFE)
so far determined show that these proteins, despite their low
sequence identities, uniformly adopt a similar fold and domain
structure: a large N-terminal and a smaller C-terminal domain,
with the active site residing at the interface between the twoFigure 2. Conserved Motifs in FadD32 and Adenylate-Forming Proteins
Structure-based amino acid sequence alignment of the FadD32 (top row) with other members of the AMP-forming family. Regions corresponding to the
conserved motifs I to IV are displayed as hatched boxes and the embedded highly conserved A3–A10 patches are delineated with solid lines above the
sequences. Black boxes indicate amino acid stretches S1–S4 found only in FadD32 proteins. For sequences aligned, darker background corresponds to higher
conservation and invariable residues are indicated by stars. MtFadD32 (M. tuberculosis FadD32, CAA17865); NfFadD32 (Nocardia farcinica FadD32,
YP_116394); PpLucif (Photinus pyralis luciferase, BAF48396); At4CL1 (Arabidopsis thaliana 4-coumarate-CoA ligase, Q42524); EcFadD (Escherichia coli
FadD, CAA50321); TtLC-FACS (Thermus thermophilus long-chain fatty acyl-CoA synthetase, BAD20228); AlcCBL (Alcaligenes sp. chlorobenzoate-CoA ligase,
AAN10109); SeACS (Salmonella enterica ser tiphymurium acetyl-CoA synthetase, AAO71645)., 510–519, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 511
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FadD32 Acyl-AMP Ligase/ACP Synthetasedomains (Conti et al., 1996, 1997; May et al., 2002; Reger et al.,
2008).
Structure-based alignment of various AFE sequences,
together with the predicted secondary elements of FadD32,
revealed the presence of four additional stretches (S1 to S4) of
amino acids of variable lengths (6–19 amino acids); S1–S3 being
exclusively found in FadD32 proteins of all Corynebacterineae
examined among other AFE (see Figure S1 available online and
Figure 2). The two central insertions S2 and S3 surround the
substrate binding pocket that comprises at least A3, A5, and
A7 sequence motifs (in the N-terminal domain of the protein),
whereas the two remaining insertions (S1 and S4) are in the close
vicinity of the acceptor binding pocket and the A8 region. Finally,
of potential importance is the long C-terminal insertion S4
following the A8-motif III (residues 534–551) that could be drawn
from this structural alignment (Figure 2). This insertion is not only
specific for FadD32 among the AFE, but also, and more impor-
tantly, is missing in the other FAAL enzymes of M. tuberculosis
(e.g., FadD26) (Figure S1). Interestingly, S4 occurs in the
FadD32 of all representatives of the genera of the Corynebacter-
ineae suborder examined except Corynebacterium (Figure S1),
a genus that produces the shortest (C32–C36) mycolic acids.
Expression and Purification of FadD32
The fadD32 gene (Rv3801c) from M. tuberculosis was cloned
and the encoded protein was produced either as a fusion with
a cleavable amino- or carboxy-terminal hexa-histidine tag.
Attempts to produce FadD32 with a C-terminal His-tag in
a soluble form were unsuccessful. The production of the
N-terminal-tagged FadD32 was induced in the E. coli BL21
(DE3) strain and purification by affinity chromatography followed
by gel filtration chromatography allowed an enrichment of the
protein with approximately a 50-fold increase in the specific
activity of the pure protein over the crude extract (Figure S2).
Depending on whether an imidazole- or a pH-gradient was
used to elute the His-tagged FadD32 from the affinity column,
distinct gel filtration elution profiles were obtained (Figure 3). In
the elution using imidazole, the profile displayed two peaks,
both of which contained FadD32, whereas a single major peak
was obtained when the protein was eluted with a pH-gradient
(Figure 3). Dynamic light scattering analysis and FAAL activity
determination (see below) of the peaks indicated that the high-
molecular-weight species (contained in peak 1, Figure 3),
presumably induced by the presence of imidazole, did not
exhibit FAAL activity. In contrast, the combined fractions from
the second peak eluted with imidazole, as well as those of the
single peak from the pH-gradient, displayed the FAAL activity
(left inset of Figure 3). Consequently, a pH gradient was
preferred for eluting His6-FadD32 from the affinity column prior
to gel filtration chromatography. SDS-PAGE and western blot
analyses using antihistidine antibodies of the FadD32-contain-
ing fractions during purification steps indicated an essentially
homogenous protein (Figure S2). The purified His6-tagged
FadD32 protein migrates on SDS-PAGE close to the predicted
molecular mass (71,395 Da) (right inset of Figure 3). Consis-
tently, size exclusion chromatography allowed estimation of
the apparent molecular mass at about 71 kDa, suggesting
that the active form of the protein is a monomer in solution
(Figure S2).512 Chemistry & Biology 16, 510–519, May 29, 2009 ª2009 ElsevierFadD32 Enzymatic Characterization and Substrate
Specificity
The FAAL activity of the purified FadD32 was determined by
radiolabeled-thin layer chromatography (radio-TLC) (Trivedi
et al., 2004). The FadD32 protein was used to generate [14C]acyl-
AMP from [1-14C]fatty acid; the substrate being subsequently
separated from the product on the basis of their differential
Rf (frontal ratio). In thepresenceof dodecanoic acid, a production
ofC12-AMPbyFadD32was observed and found to be both ATP-
and Mg2+-dependent (Figure 4A); expectedly, the presence of
CoA in the mixture did not result in the production of acyl-CoA
(Trivedi et al., 2004), demonstrating that the purified FadD32
possessed a FAAL activity in our in vitro assay. The FadD32
enzyme exhibited typical Michaelis-Menten profiles when its
acyl-adenylation activity was determined using increasing
concentrations of fatty acid (Figure S3). To determine the
FadD32FAAL-specificactivity, theacyl-AMPformationasa func-
tion of enzyme concentration was measured (Figure 4B). The
optimal conditions for the measurement of the initial velocity
weredetermined (FigureS4). The responsewas linear in the range
of FadD32 concentrations tested (up to 2.4 mM and 0.8 mM with
C12 and C14 fatty acid substrates, respectively). Under standard
assay conditions, the enzyme was much more active when C14
was used as substrate, compared with C12 (Figure 4B). The
specific activities calculated for the enzyme (at 20 mM of
substrate) were 0.32 ± 0.02 and 1.59 ± 0.21 nmol min1 mg1
protein for C12 and C14, respectively. It is worth noting that the
value obtained in the presence of the latter substrate was similar
to that of the E. coli fatty acyl-CoA synthetase FadK (1 nmol C14-
CoA min1 mg1 [Morgan-Kiss and Cronan, 2004]).
To gain insight into the substrate specificity of FadD32, the
protein was incubated with a panel of commercially available
Figure 3. Purification, Activity, and Aggregation State of His6-
FadD32
Elution profile of His6-FadD32 using a gel filtration (Superdex 200) column after
a first step of affinity chromatography was performed using either an imidazole
(blue trace) or pH gradient (red trace) for elution. Fatty acyl-AMP ligase (FAAL)
activity in peaks 1 and 2 derived from the imidazole purification (left inset);
means and standard error of the mean (SEM) of two replicates are shown,
and data are representative of three independent experiments. Fractions
from the Superdex 200 major peak obtained in the pH-gradient purification
were pooled and analyzed by SDS-PAGE (right inset).Ltd All rights reserved
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FadD32 Acyl-AMP Ligase/ACP Synthetaseradiolabeled fatty acids, from C4 to C16, and the acyl-adenyla-
tion activity was determined. The FadD32 substrate selectivity
profile was compared with those of two FACS, namely the
E. coli FadK and the Mycobacterium avium Mig, known to
display, respectively, short-chain and medium-chain length
specificity. The latter proteins were expressed and purified as
described (Morgan-Kiss and Cronan, 2004; Morsczeck et al.,
2001) and their FACS activity was tested in a typical FadD32
radio-TLC assay containing CoA and using [1-14C]labeled fatty
acids at a fixed concentration. Whereas FadK and Mig exhibited
substrate preferences centered on C8-C12 and C8-C14 fatty
CA
B
Figure 4. FadD32 Fatty Acyl-AMP Ligase (FAAL) Activity and Acyl
Chain-Length Selectivity
(A) The FAAL activity and the requirements of FadD32. The assays contained
the indicated components and were initiated either with the enzyme (2 mM) or
with [1-14C]C12:0 fatty acid (50 mM) in the minus-enzyme assay. The reaction
products were separated by TLC and detected by autoradiography; migration
origin (O) and front (F). The TLC profile shown is representative of two repli-
cates. [14C]C16-CoA (lane 6) and cold C12-AMP (lane 7) were used as stan-
dards; the latter synthetic product was detected after spraying the plate with
rhodamine B and observation under UV (the spot was highlighted for clarity).
(B) Specific activity of FadD32 using either [1-14C]C12:0 (B) or [1-14C]C14:0 (d)
as substrate.
(C) The enzymatic activities of His6-FadK, His6-Mig and His6-FadD32 were
determined in the presence of 20 mM of the indicated [1-14C]fatty acids with
different chain lengths. Incorporation of radioactivity into product, acyl-CoA
(for FadK and Mig) or acyl-AMP (for FadD32), was displayed as percentages
of the total radioactivity (including those contained in the spot [remained at
the origin], substrate and product). The graph showing FadD32 selectivity is
representative of two independent experiments.Chemistry & Biology 16acids, respectively, FadD32 was most active when C14 was
used as substrate (Figure 4C).
In order to investigate further the enzymatic properties
of FadD32, kinetic parameters for selected chain fatty acid
substrates (C12, C14, and C16) were determined. FadD32
displayed typical Michaelis-Menten profiles (Figure S3) and con-
verted C12:0, C14:0 and C16:0 to their respective acyl-adeny-
lates, with the enzyme affinity and catalytic efficiency (kcat/Km)
increasing with the chain length of the substrate (Table S1).
Expectedly, FadD32 demonstrated the highest affinity (Km of
3.2 mM) toward C16, 1000-fold increased as compared with
that toward C12. In terms of catalytic efficiencies, the C16 and
C14 represented the most efficiently converted substrates,
with kcat/Km of 4.7 and 6.2 mM
1 min1, respectively; 80- to
100-fold higher than that for C12 (Table S1). The apparent
activity of the enzyme with C4 and C8 was too low for activity
determination in the standard FAAL assay. The purified FadD32
showed a Km of 2 mM for ATP (Table S1), which is in the same
order of magnitude of those described for other FACS (Hall
et al., 2005; Rusnak et al., 1989). Thus, determination of
FadD32 catalytic constants for substrates indicated again that
the protein displays a preference for long-chain over medium-
and short-chain fatty acid substrates.
To assess the specificity of FadD32 for longer substrates,
a competitive kinetic assay was performed because of the
unavailability of commercially radiolabeled fatty acids longer
than C20. The competing long- and very long-chain fatty acids
were added at a fixed concentration to the reaction containing
increasing concentrations of [14C]substrate (Figure S5); C16
was chosen for these experiments, based on the high affinity of
the enzyme toward this substrate (see above). The formation of
C16-AMP by FadD32 as a function of [14C]C16 concentration in
the absence or presence of cold C16 showed typical curves
of efficient competitive binding (Figure S5). Unexpectedly,
however, the addition of 10 mM C20 or C24 resulted in binding
curves with higher rate (Vmax) values than the control without
competitor (Figure S5). This reproducible observation suggested
the occurrence of an underlying phenomenon, reminiscent of
a ‘‘detergent’’ effect, probably due to the long aliphatic chains
of the competitors tested. Consistently, the addition of low
concentrations (0.1%) of Triton X-100 to FadD32 assays signifi-
cantly improved the enzyme activity (Figure S5). Further attempts
to improve the experimental conditions for these competitive
binding assays in order to dissect the effect of long-chain
substrates on FadD32 activity were unsuccessful.
Structural Features of FadD32 Suggestive
of an Additional Acylation Activity
From structural and biochemical studies with acetyl-CoA
synthetase (Acs) and chlorobenzoyl-CoA ligase (CBL) (Reger
et al., 2007, 2008), the adenylate-forming enzymes have been
proposed to have a ‘‘domain alternation’’ type of catalysis, where
conformational changes take place and define either an adeny-
late- or a thioester-forming conformation, the two conformational
states being in equilibrium. The role of the domain movement
would be to remove stabilizing residues that are necessary for
the adenylation half-reaction from the active site and simulta-
neously create a binding pocket for the phosphopantetheine
(P-pant) of the acceptor. Key residues involved in both, 510–519, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 513
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FadD32 Acyl-AMP Ligase/ACP Synthetaseconformations are found conserved in FadD32 (Figure 2), with the
Lys608 (in A10-motif IV) essential for the adenylate-forming
conformation and Gly499 (in A8-motif III), ensuring the thioester-
forming conformation by hydrogen bonding to the P-pantmoiety,
as shown for Acs andCBL (Reger et al., 2007, 2008). Importantly,
the conservation of this glycine in FadD32 was suggestive of
the enzyme acylation activity (acyl-CoA/ACP) because kinetic
analysis of an Acs mutant in this residue (Gly to Leu) was only
active for the adenylate-forming half-reaction (Reger et al., 2007).
Thus, the alignment of FadD32 with acyl-adenylate-forming
enzymes (Figure 2) suggested that the protein would catalyze
the two half-reactions usually performed by FACS and fatty
acyl-ACP synthetase (FAAS) enzymes (Figure 1). In addition, as
stated above, the exclusive occurrence of the long C-terminal
insertion S4 following the A8-motif III (Figure 2) in FadD32
among both the AFE and the other FAAL of M. tuberculosis
FadD points to the potential interaction of FadD32 with the
P-pant moiety of an ‘‘acceptor’’ molecule/domain and to specific
features of the protein of possible importance in catalysis and/or
substrate specificity.
FadD32 Displays Acyl-ACP Synthetase Activity
To investigate the possible acylation activity of FadD32 and
determine its ‘‘acceptor’’ selectivity, several substrates (CoA,
ACP, AcpM, Pks13) were tested in modified FAAL, FACS, and
FAAS assays using FadD32 or control enzymes, i.e., E. coli
FadK (a FACS enzyme) and Aas (a FAAS protein), purified as
described previously (Morgan-Kiss and Cronan, 2004; Shanklin,
2000). In the presence of CoA, FadD32, unlike FadK, was unable
to convert the C14-AMP (formed from [1-14C]C14 andATP) to the
corresponding acyl-CoA (Figure 5C, lanes 3 and 4), as expected
(Trivedi et al., 2004). To investigate whether FadD32 could
acylate ACP, the enzyme was mixed with either E. coli holo-
ACP orM. tuberculosis holo-ACP (holo-AcpM) and the formation
of labeled C14-ACP was analyzed by conformationally sensitive
gel electrophoresis (Post-Beittenmiller et al., 1991; Rock et al.,
1981) (Figure 5A). In the presence of holo-ACP, no acyl-ACP
was detected when FadD32 was used in the assay, unlike the
high acyl-ACP synthetase activity observed with Aas (Figure 5A,
lanes 2 and 3). In contrast, in the presence of AcpM, FadD32
showed a significant acylation activity, as demonstrated by the
formation of labeled acyl-AcpM, comparable to that measured
for the acyl-ACP synthetase Aas in the presence of holo-AcpM
(Figure 5A lower panel, lanes 4 and 5). Finally, the radiolabeling
associated with the Pks13 protein (Figure 5B, lower panel,
lane 3), likely due to the transfer of [14C]acyl chain from the inter-
mediate C14-AMP onto the protein, was specifically observed
in the presence of FadD32, but not in that of Aas (Figure 5B, lanes
2 and 3). These data demonstrated that, in addition to its
FAAL activity, FadD32 functions as an acyl-ACP ligase in vitro
and that this acylation activity is highly specific and restricted
to a limited number of ‘‘acceptors,’’ namely, AcpM and the
condensing enzyme Pks13, the latter being probably the natural
and most efficient substrate.
In order to investigate the molecular basis of the FadD32
specificity toward ACPs from different sources, a bioinformatic
analysis was performed (Figure 6). Alignment of E. coli ACP
and AcpM indicates a high degree of similarity between the
proteins, especially in the four-helix bundle ACP fold (residues514 Chemistry & Biology 16, 510–519, May 29, 2009 ª2009 Elsevier1–82) at their N termini, while the particularity of AcpM resides
in an extended carboxyl-terminus (residues 83–115). Strikingly,
the N-ACP (amino-terminal ACP) domain of Pks13, onto which
the transfer of the acyl chain from FadD32 to the condensase
has been suggested to occur (Trivedi et al., 2004), also displays
such an extension. Despite the relatively low degree of similarity
A
C
B
Figure 5. Determination of the Acceptor Selectivity of FadD32
In Vitro
All reactions used [1-14C]C14:0 as substrate in a standard FAAL, FACS, or
FAAS assay.
(A) The FadD32 acylation activity in the presence of either E. coli holo-ACP or
M. tuberculosis holo-AcpM was analyzed by urea-PAGE (2.5 M, 15%) (Post-
Beittenmiller et al., 1991; Rock et al., 1981). The assays included Aas (1 mM)
or FadD32 (4 mM); lane 1 contains holo-ACP and lane 6, holo-AcpM (with the
two distinctive bands that correspond to the monomer [AcpMm] and disulfide
dimer [AcpMd]).
(B) Loading of the labeled acyl chain from C14-AMP (generated using either
Aas [0.6 mM] or FadD32 [2.1 mM]) onto Pks13 (3.6 mM) analyzed by SDS-
PAGE. Detection in (A) and (B) was by Coomassie staining and by autoradiog-
raphy in upper and lower panels, respectively.
(C) Radio-TLC analysis of FadD32 products using CoA as acceptor. The E. coli
FadK, a FACS, was used as a control for the synthesis of acyl-CoA (lane 4);
both enzymes were added at 2.1 mM, and lane 5 contained a [14C]C16-CoA
standard.Ltd All rights reserved
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FadD32 Acyl-AMP Ligase/ACP SynthetaseFigure 6. Structure-Based Amino Acid
Sequence Alignment of ACPs
The four-helix bundle characteristic of the ACP fold
is displayed for AcpM (Wong et al., 2002). Black and
grayshadings indicatestrictlyconservedandsimilar
residues, respectively, and a star indicates the
conserved serine residue where the prosthetic
group binds. MtAcpM (M. tuberculosis AcpM,
CAA94640);Mtpks13ACP1(N-terminalACPdomain
of M. tuberculosis Pks13, CAA17864); EcACP
(E. coli ACP, AAB27925).between the two C-terminal extensions, AcpM and the N-ACP
domain of Pks13 sequences align quite well (Figure 6), suggest-
ing that this common feature very likely plays a role in deter-
mining the specificity of the FadD32-acceptor interaction.
Inhibition of FadD32 Activity
The ultimate goal of identifying and characterizing essential and
specific proteins of the tubercle bacillus is their use as novel
targets for the development of new antituberculous drugs.
FadD32 is one of these newly discovered candidates (Portevin
et al., 2005). Various nonhydrolyzable acyl-AMP analogs have
been recently used as mechanism-based inhibitors, which were
found to be potent inhibitors of related adenylate-forming
enzymes (Arora et al., 2009; Ferreras et al., 2005, 2008). Adeno-
sine 50-alkyl phosphates, are structural analogs of adenosine
50-acyl phosphates (acyl-AMP) (Figure 7A, (1)), the transient inter-
mediates of the acyl-CoA/ACP synthetic reaction (Figure 1).
Based on these considerations, we postulated that the reaction
intermediate mimic adenosine 50-dodecylphosphate (alkyl-
adenylate, AMPC12, Figure 7A (2)), known to inhibit many FACS
(Grayson and Westkaemper, 1988; Shiraishi et al., 1994), would
be a potent inhibitor of the acyl-adenylation activity of FadD32.
We chemically synthesized AMPC12 as described previously
(Machida et al., 1997) and checked its structure by mass spec-
trometry and nuclear magnetic resonance (see Supplemental
Data). We first tested the inhibitory effect of the synthesized alkyl
phosphate on the acyl-CoA synthetase FadK from E. coli. In a
typical acyl-AMP ligase assay containing [1-14C]fatty acid and
CoA as substrates, AMPC12 showed a significant inhibition on
the FadK activity (85%of the original level at 2 mM). The inhibitory
effect of the AMPC12 on FadD32 activity was then examined by
varying the inhibitor concentration (0.05–10 mM) at a fixed
concentration (100 mM) of the fatty acid substrate ([14C]C14). As
shown in Figure 7B, the AMP analog inhibited the activity of the
enzyme in a concentration-dependent manner, reducing it by
almost 90% of the original level at 2 mM, remarkably comparable
to the effect of the inhibitor on FadK. The calculated half-maximal
effective concentration (EC50) of the AMPC12 compound corre-
sponds to 0.11 mM, which is less than 20 times the enzyme
concentration used in the assay. Because the AMPC12 was
active on FadD32, we investigated whether this AMP analog
could influence the mycobacterial growth. For this purpose,
Mycobacterium smegmatis mc2155 cells (OD600 of 0.02) were
incubated in 96-well plates at 37C in the presence of increasing
concentrations (8–75 mM) of AMPC12 and their viability was
monitored after 48 hr using the tetrazolium salt assay (Sieuwerts
et al., 1995). The same concentrations of AMPC12were tested in
parallel on growing cells of Corynebacterium glutamicum andChemistry & Biology 16E. coli. The addition of AMPC12 to M. smegmatis induced
a dose-dependent inhibition of growth with more than 80% loss
of viability at 19 mMof the inhibitor (Figure 7C). At this concentra-
tion, about 45% growth impairment of C. glutamicum was
observed whereas E. coli was almost insensitive to AMPC12.
BecauseM. smegmatis and C. glutamicumwere the most sensi-
tive to AMPC12, we hypothesized that these mycolic-acid-
synthesizing bacteria have their mycolic acid metabolism
affected by the synthetic analog. We therefore examined the
inhibitory effect of AMPC12 on fatty acid/mycolic acid synthesis
inM. smegmatis using a cell-free extract (CFE) synthesizingmost
exclusively mycolic acids (Lacave et al., 1990). AMPC12 was
pre-incubated with CFE for 30 min and the synthesis of
[1-14C]acetate-labeled fatty acids andmycolic acidswasallowed
for 60 min before lipids were extracted and analyzed. Although
no effect on fatty acid synthesis was observed at a subinhibitory
concentration of AMPC12 (10 mM), an inhibition of 40% of the
synthesis of all types of M. smegmatis mycolic acids (alpha,
alpha0, epoxy) was observed (data not shown). These results indi-
cated that AMPC12 could reach its target within the particular
system of CFE and that inhibition of mycolic acid synthesis
occurs very likely through the inhibition of FadD32 activity.
DISCUSSION
The present study was undertaken in order to characterize the
enzymatic properties of FadD32, a protein essential for mycolic
acid synthesis, and define its substrate specificity. From its
chromatographic behavior, the His6-FadD32 appeared active
as a monomer in solution. It is unknown, however, whether
FadD32 exists as a monomer in the ‘‘condensing complex’’
in vivo where it possibly engages interaction(s) with its partners,
Pks13 and AccD4. Expectedly, the purified FadD32 possessed
an acyl-AMP ligase activity in vitro and was able to synthesize
acyl-adenylates from fatty acids and ATP in the presence of
Mg2+. Investigation of detailed kinetic properties of the enzyme
showed that FadD32 exhibited the strongest affinity toward
C16 fatty acid and best catalytic efficiencies toward C16:0 and
C14:0 acids. These properties distinguish FadD32 from the
(middle-chain) acyl-CoA synthetase Mig of M. avium, whose
substrate specificity is centered on C10 (Morsczeck et al.,
2001). FadD32 thus presents an apparent selectivity profile
centered on C14-C16 and can be classified as a long-chain
acyl-AMP ligase in vitro. For a matter of unavailability of very
long-chain radiolabeled molecules, we used cold fatty acids
in a competitive kinetic assay to investigate the specificity of
FadD32 for very long-chain substrates (Figure S5). Because
a ‘‘detergent’’ effect was invariably observed in the presence, 510–519, May 29, 2009 ª2009 Elsevier Ltd All rights reserved 515
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not be studied in the presence of its presumed natural substrates
in mycobacteria, i.e., C54–C64 meromycolic acids. Compared
with specific activities described for short- or medium-chain
FACS from the same family (S. enterica Acs [Ingram-Smith
et al., 2006], E. coli FadD [Morgan-Kiss and Cronan, 2004],
M. avium Mig [Morsczeck et al., 2001]), the M. tuberculosis
FadD32 exhibits a relatively low activity toward middle- to
long-chain substrates (C12–C16), which probably reflects the
low catalytic efficiency of the protein in the presence of these
relatively ‘‘short’’ substrates as compared with the natural
substrates. Elements from amino acid alignment of FadD32
with other AMP-forming proteins and short-chain acyl-CoA
synthetases corroborate this result (Figure 2). Indeed, among
the specific amino acid residues shown to be involved in chain
length selectivity of proteins from this superfamily (Black et al.,
1997; Ingram-Smith et al., 2006) is a Gly that is present in
FadD32 (Gly351 in motif II, Figure 2), whereas in the aligned
sequence of the S. enterica short-chain acyl-CoA synthetase
Acs, a Trp is found in lieu of the Gly residue. Interestingly, in
the case of the S. enterica Acs that has a preference for acetate
and propionate, the removal of the equivalent Trp416 side chain
from the hydrophobic pocket was sufficient to enlarge the
pocket to accommodate longer substrates (Ingram-Smith
et al., 2006).
A
B C
Figure 7. Inhibitory Effect of Dodecyl-AMP (AMPC12) on FadD32
Activity and on Bacterial Growth
(A) Chemical structures of acyl-adenylate intermediate (acyl-AMP, (1)) and its
analog, adenosine 50-alkylphosphate (alkyl-AMP, AMPC12, (2)), R = C12.
(B) FadD32 activity in the presence of increasing concentrations of AMPC12
was determined in a typical radio-TLC assay (using 100 mM [1-14C]C14:0 as
substrate and 2.1 mMenzyme). Data shown are representative of two indepen-
dent experiments.
(C) Bacterial growth inhibition curves ofM. smegmatismc2155 (-),C. glutami-
cum ATCC13032 (A), and E. coli DH5a (:) strains in the presence of
increasing concentrations of AMPC12 were determined. ODT/ODC, ratio of
OD580nm of inhibitor-treated (ODT) to OD580nm of control cultures (ODC),
DMSO-treated. Data show the mean of two replicates.516 Chemistry & Biology 16, 510–519, May 29, 2009 ª2009 ElsevierThe very-long-chain acyl-adenylates produced by FadD32 are
the putative activated substrates for the condensation reaction
catalyzed by Pks13. The resulting meromycoloyl chains should
then be transferred onto the N-ACP domain of Pks13 by either
a yet unknown enzyme or FadD32 that would then necessarily
possess an unrevealed additional function (Gavalda et al.,
2009). Investigation of the putative additional acyl-ACP synthe-
tase function of FadD32 led to the demonstration that the enzyme
is also able to acylate the mycobacterial AcpM. Thus, FadD32
would not simply be a ‘‘fatty acyl-AMP ligase,’’ as previously
suggested (Trivedi et al., 2004), but rather would catalyze the
two half-reactions usually performed by FadD enzymes, i.e.,
the production of an acyl-AMP from a fatty acid and ATP, then
the transfer of the acyl chain from the acyl-AMP onto the P-pant
moiety of a substrate, the natural one being in the present case
Pks13. It is noteworthy that among the 12 FadD proteins of
M. tuberculosis previously classified as FAAL (Trivedi et al.,
2004), 9 have their gene located near a pks that includes an acp
sequence or near an acp-like gene (Table S2). The enzymes
belonging to this subfamily are likely to have the function of
producing ACP/PCP (peptidyl carrier protein) derivatives. Thus,
with respect to their substrate specificity, FadD enzymes would
either synthesize acyl-CoA or acyl-ACP/PCP molecules, the
ACP or PCP being either free-standing proteins or PKS- and
NRPS-associated domains. It is noteworthy that Cronan’s group
has recently reported thecharacterization of an acyl-ACPsynthe-
tase from Vibrio harveyi that was previously classified as a
member of the acyl-CoA synthetase family (Jiang et al., 2006).
In this regard, FadD32wouldbeaprototypeof theM. tuberculosis
FadD proteins classified as FAAL, where these adenylate-form-
ing enzymes associated to pks genes would catalyze ACP-acyl-
ation reactions. In agreement with this hypothesis, we have
observed that another FadD protein, namely FadD26, also
possesses an acyl-ACP activity (our unpublished data).
As an acyl-ACP synthetase, FadD32 is capable of acylating
the mycobacterial AcpM but neither ACP from E. coli nor CoA,
the N-terminal domain of Pks13 being its very likely natural and
highly specific in vivo acceptor. These results strongly suggest
that specific features of AcpM versus E. coli ACP and/or speci-
ficity of the interaction FadD32-acceptor domain might be
involved. This assumption was further supported by the bioinfor-
matic analysis of ACP from different sources. The alignment of
the protein sequences shows a high degree of similarity at their
N termini, yet AcpM has an extended carboxyl-terminus that
aligns quite well with the sequence of the N-ACP domain of
Pks13 despite their low degree of similarity. This suggests that
this common feature very likely plays a role in determining the
molecular basis underlying the chain-length specificity of fatty
acyl intermediates during mycolic acid biosynthesis.
Finally, as a first step in the validation of FadD32 as a good
target for the search of new antituberculous drug, we showed
that the alkylphosphate ester of AMP, adenosine 50-dodecyl-
phosphate (AMPC12), inhibited the acyl-AMP ligase activity of
FadD32. This reasoning was based on the observed inhibition
of many FACS by this molecule. This compound has a structure
analogous to acyl-AMP, the transient intermediate of the acyl-
CoA/ACP synthetic reaction (Figure 1). Furthermore, AMP
analogs were recently reported as potent inhibitors of acyl- and
aryl-adenylation domains of enzymes involved in the productionLtd All rights reserved
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2005, 2008). Indeed, AMPC12, which also inhibited both mycolic
acid synthesis and mycobacterial growth, is an efficient inhibitor
of FadD32. Based on the inhibition data presented herein,
AMPC12 represents a promising tool for the study of substrate
binding pocket and three-dimensional structure determination
in complex with FadD32. Further insights into the enzymatic
mechanism will require the structure determination of enzyme-
ligand complexes to search for efficient inhibitors in the perspec-
tive of antimycobacterial drug development.
SIGNIFICANCE
Mycolic acids aremajor and specific lipid components of the
mycobacterial cell envelope, and essential for the survival of
members of the genus, which contains numerous human
and animal pathogens. Understanding the biosynthesis of
these critical determinants of both the mycobacterial
permeability and virulence is an important goal, because it
might lead to design of new antituberculous drugs. FadD32
is an FAAL that activates the very long meromycolic acid
(C50–C60) condensed by Pks13 with a C22–C26 fatty acid to
yield, after reduction, mycolic acids. The findings reported
here demonstrate the biochemical and enzymatic properties
of FadD32 and show that, in addition to the previously recog-
nized FAAL activity, the protein possesses an acyl-ACP
ligase function. Moreover, to the best of our knowledge,
FadD32 is the firstM. tuberculosis FAAL reported to possess
such an activity and might be the prototype of a group of
polyketide-synthase-associated adenylation enzymes with
an uncommon catalytic mechanism. The substrate analog
dodecyl-AMP efficiently inhibited the FadD32 activity, my-
colic acid biosynthesis and mycobacterial growth. Overall,
these studies advance our understanding of the biosyn-
thesis of the hallmark of mycobacteria and open an avenue
for the development of mechanism-based novel antimyco-
bacterial agents.
EXPERIMENTAL PROCEDURES
Bioinformatic Sequence Analysis
Amino acid sequences were obtained from the National Center for Biotech-
nology Information. Alignments were performed using the Clustal W2 program
(Larkin et al., 2007) and manually adjusted in Seaview (Galtier et al., 1996); the
figures were shaped using Espript (Gouet et al., 1999).
Cloning and Purification of FadD32 (His6-FadD32)
The cloning and purification of FadD32 are described in detail in the Supple-
mental Data. Briefly, the M. tuberculosis H37Rv fadD32 gene was amplified
by polymerase chain reaction and the insert was ligated into the pET15b
E. coli expression vector (Novagen). The FadD32 expression was induced
5 hr at 25C in E. coli BL21(DE3) cells. The cleared lysate expressing
FadD32 was applied to HisTrap HP affinity column and elution of the protein
was performed using either an imidazole or pH gradient. The FadD32-contain-
ing fractions were applied to a gel filtration chromatography (Superdex 200)
column; the protein was homogeneous as judged by SDS-PAGE (Laemmli,
1970) and western blot analysis using anti-polyHis antibodies (detailed in
Supplemental Data).
Enzymatic Assays for Acyl-AMP/ACP Ligase Activity
Enzymatic activity was determined by monitoring acyl-AMP formation using
radio- TLC in which labeled fatty acid in the presence of ATP was convertedChemistry & Biology 16into acyl-AMP that was separated from the substrate by TLC and detected
by autoradiography (Trivedi et al., 2004). The standard FAAL reaction mixture
included 100 mM Tris-HCl (pH 7), 20–100 mM [14C]fatty acid, 2 mM ATP, 8 mM
MgCl2 and 0.2–3.6 mg protein in a 15 ml reaction volume. In the case of deter-
mination of FACS activity, 2 mM CoA was added to the mixture. The reaction,
performed for 10 min at 30C, was initiated by the addition of the enzyme,
terminated by the addition of 5% acetic acid, and spotted on silica gel TLC
plates (G60). Radiolabeled products were resolved in butan-1-ol/acetic acid/
water (80:25:40) at room temperature and visualized by exposing the TLC to
Fujifilm imaging plate prior to phosphorimager detection (Typhoon Trio GE
Healthcare). A standard curve of labeled [14C]fatty acid substrate allowed
[14C]acyl-AMP quantification using the ImageQuant software version 5.1
(Molecular Dynamics).
For FAAS/ligase activity determination, the reaction mixture (15 ml) con-
tained 100 mM [1-14C]C14 fatty acid, 2 mM DTT, 10 mM MgCl2, 5 mM ATP
in 100 mM Tris-HCl (pH 7), and 15–25 mM of ACP or AcpM, the latter being
produced and purified as reported (Kremer et al., 2000). Reactions were
started with the addition of enzyme and incubated for 2 hr at 30C. For acyl-
ACP and acyl-AcpM detection, 10–15 ml of reactions were analyzed by urea-
PAGE (15% polyacrylamide gel containing 2.5 M urea [Kremer et al., 2000;
Post-Beittenmiller et al., 1991; Rock et al., 1981]). To test the loading of the
acyl chain from acyl-AMP (generated by FadD32) onto the Pks13 protein (puri-
fied as reported in Gavalda et al., 2009), the same reaction mixture was used
except for the buffer (100 mM HEPES [pH 7] replaced Tris buffer); separation
was performed by 12% SDS-PAGE. The labeled products were detected
using phosphorimager.
Mycolic Acid Synthesis Assay and Analysis
The CFE synthesizingmycolic acids was prepared fromM. smegmatismc2155
as described (Lacave et al., 1990). AMPC12 was added to the CFE for 30 min
and the neosynthesis of fatty acids, including mycolic acids, was followed by
the addition of 50 mm of [1-14C]acetate as a precursor. The reaction was
stopped 60 min later by saponification and lipids were extracted with diethyl
ether. The effect of the AMPC12 on the incorporation of radioactivity into non-
hydroxylated fatty acid methyl esters and mycolic acid methyl esters was
determined.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, five
figures, and two tables and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00147-1.
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